Teleflex TFX · NYSE
$135.83 -0.55% (-$0.75)
Summary
38 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- Out of every 100 USD of revenue, 15 USD is left as free cash.
- It bought back its own shares for $300.0M in the last fiscal year, 5.2% of its market value.
- Analysts expect revenue to grow by 14% this fiscal year.
What to watch
- The company made a loss over the last 12 months.
- Revenue fell by 11% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 4.7% a year over 5 years. Over the last 3 years it fell by 11% a year. For the next fiscal year analysts expect revenue to grow by 14%.
Growth in detailDoes it make money?
ReasonablyOver the last 12 months it made a loss of $1.03B.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 7.4 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 1.00%
You receive $1.36 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 16
- Hold 13
- Sell 0
Today's price within the analysts' price targets
The average target of $155.25 is 14% above today's price. 55% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Vascular Access 46%
- Interventional 33%
- Surgical 21%
- Other 0.5%
By region
- UNITED STATES 63%
- EMEA 26%
- Asia 12%
Vascular Access brings in 46% of revenue. Interventional grew fastest, by 11% a year.
Segments in detail